Table 2.
Comparative analysis of clinical and endoscopic characteristics in early and late UST use groups at different time points.
| Characteristics | Early UST use (n = 105) | Late UST use (n = 132) | Q value | ||||
|---|---|---|---|---|---|---|---|
| Baseline | 6-month follow-up | p Value | Baseline | 6-month follow-up | p Value | ||
| Clinical characteristics | |||||||
| BMI, kg/m2, median (IQR) | 18.4 (17.0, 20.2) | 19.5 (18.1, 21.1) | 0.008 | 19.4 (17.7, 21.7) | 19.8 (17.9, 21.8) | 0.290 | 0.472 |
| CRP, mg/L, median (IQR) | 6.3 (2.4, 27.9) | 3.0 (0.8, 6.9) | <0.001 | 8.0 (2.2, 20.5) | 2.7 (0.9, 8.9) | <0.001 | 0.643 |
| WBC, ×109/L, median (IQR) | 6.5 (5.1, 8.5) | 6.3 (5.0, 7.3) | 0.115 | 6.3 (4.9, 7.5) | 6.0 (5.0, 7.3) | 0.460 | 0.572 |
| Hemoglobin, g/L, median (IQR) | 122.0 (102.0, 136.0) | 130.0 (117.0, 143.0) | 0.006 | 123.5 (104.0, 138.0) | 128.0 (112.0, 139.3) | 0.177 | 0.106 |
| PLT, ×109/L, median (IQR) | 314 (255, 388) | 264 (220, 318) | <0.001 | 290.5 (247, 360) | 257.0 (212, 317) | 0.003 | 0.898 |
| Albumin, g/L, median (IQR) | 38.4 (33.3, 42.0) | 39.7 (37.3, 42.2) | 0.021 | 38 (34.6, 41.4) | 38.0 (35.8, 40.3) | 0.726 | 0.002 |
| CDAI, median (IQR) | 226.4 (191.0, 270.6) | 137.0 (117.0, 148.0) | <0.001 | 230.0 (198.8, 272.3) | 168.0 (147.8, 199.1) | <0.001 | <0.001 |
| Clinical remission, n (%) | 0 (0.0) | 80 (76.2) | – | 0 (0.0) | 37 (28.0) | – | <0.001 |
| Endoscopic characteristics | |||||||
| SES-CD, median (IQR) a | 8.5 (5.0, 15.0) | 2.5 (1.0, 6.0) | <0.001 | 10.0 (5.0, 15.0) | 4.0 (3.0, 10.0) | <0.001 | 0.003 |
| Rutgeerts score ⩾i2, n (%) b | 5 (100.0) | 2 (40.0) | – | 40 (90.9) | 34 (77.3) | 0.080 | – |
| Endoscopic remission, n (%) c | 4 (4.2) | 48 (50.5) | – | 6 (5.7) | 25 (23.8) | – | <0.001 |
Q value refers to the statistics comparisons between early and late UST use groups at 6 months follow-up.
Data available in 90 patients in early UST use group and 61 patients in the late UST use group.
Data available in 5 patients in the early UST use group and 44 patients in the late UST use group.
Data available in 95 patients in the early UST use group and 105 patients in the late UST use group at baseline.
BMI, body mass index; CDAI, Crohn’s disease activity index; CRP, C-reactive protein; IQR, interquartile range; PLT, blood platelet; SES-CD, Simple Endoscopic Score for Crohn’s disease; UST, Ustekinumab; WBC, white blood cell.